Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 2 records in total 2
    records per page




    Performance SERO of serum SERO apolipoprotein-A1 as a sentinel of Covid-19

    Authors: Thierry Poynard; Olivier Deckmyn; Marika Rudler; Valentina Peta; Yen Ngo; Mathieu Vautier; Sepideh Akhavan; Vincent Calvez; Clemence Franc; Jean Marie Castille; Fabienne Drane; Mehdi Sakka; Dominique Bonnefont-Rousselot; Jean Marc Lacorte; David Saadoun; Yves Allenbach; Olivier Benveniste; Frederique Gandjbakhch; Julien Mayaux; Olivier Lucidarme; Bruno Fautrel; Vlad Ratziu; Chantal Housset; Dominique Thabut; Patrice Cacoub; Fredrik Nyberg; Jose D Posada; Christian G Reich; Lisa M Schilling; Karishma Shah; Nigham H Shah; Vignesh Subbian; Lin Zhang; Hong Zhu; Patrick Ryan; Daniel Prieto-Alhambra; Kristin Kostka; Talita Duarte-Salles

    doi:10.1101/2020.09.01.20186213 Date: 2020-09-03 Source: medRxiv

    Background Since 1920, a decrease in serum SERO cholesterol has been identified as a marker of severe pneumonia HP pneumonia MESHD. We have assessed the performance SERO of serum SERO apolipoprotein-A1, the main transporter of HDL-cholesterol, to identify the early spread of coronavirus disease MESHD 2019 (Covid-19) in the general population and its diagnostic performance SERO for the Covid-19. Methods We compared the daily mean serum SERO apolipoprotein-A1 during the first 34 weeks of 2020 in a population that is routinely followed for a risk of liver fibrosis MESHD risk in the USA (212,297 sera) and in France (20,652 sera) in relation to a local increase in confirmed cases TRANS, and in comparison to the same period in 2019 (266,976 and 28,452 sera, respectively). We prospectively assessed the sensitivity SERO of this marker in an observational study of 136 consecutive hospitalized cases and retrospectively evaluated its specificity in 7,481 controls representing the general population. Results The mean serum SERO apolipoprotein-A1 levels in the survey populations began decreasing in January 2020, compared to the same period in 2019. This decrease was highly correlated with the daily increase in confirmed Covid-19 cases in the following 34 weeks, both in France and USA, including the June and mid-July recovery periods in France. Apolipoprotein-A1 at the 1.25 g/L cutoff had a sensitivity SERO of 90.6% (95%CI84.2-95.1) and a specificity of 96.1% (95.7-96.6%) for the diagnosis of Covid-19. The area under the characteristics curve was 0.978 (0.957-0.988), and outperformed haptoglobin and liver function tests. The adjusted risk ratio of apolipoprotein-A1 for survival without transfer to intensive care unit was 5.61 (95%CI 1.02-31.0;P=0.04). Conclusion Apolipoprotein-A1 could be a sentinel of the pandemic in existing routine surveillance of the general population. NCT01927133, CER-2020-14.

    Clinical Characteristics Hospitalized Patients with SARS-Cov-2 and HBV Co-infection MESHD

    Authors: Xiaoping Chen; Qunqun Jiang; Zhiyong Ma; Jiaxin Ling; Wenjia Hu; Qian Cao; Pingzheng Mo; Rongrong Yang; Shicheng Gao; Xien Gui; Yong Xiong; Jinlin Li; Yongxi Zhang

    doi:10.1101/2020.03.23.20040733 Date: 2020-03-27 Source: medRxiv

    Background & Aims The coronavirus disease MESHD 2019 (COIVD-19) caused by SARS-CoV-2 has been characterized as a pandemic, which causes a serious public health challenge in the world. A very large group of patients infected by HBV has been reported worldwide, especially in China. In order to answer whether specific treatment strategy on the patients coinfected with HBV and SARS-CoV-2, it requires profound understanding of the clinical characteristics on those patients. However, the impacts of SARS-CoV-2 infection MESHD on HBV patients remain largely unknown. Approach & Results In this retrospective investigation, we included 123 COVID-19 patients admitted to Zhongnan Hospital of Wuhan University, Wuhan, China, from January 5 to March 7, 2020. All enrolled patients are the laboratory confirmed COVID-19 pneumonia HP pneumonia MESHD cases according to the criteria reported previously. A total of 123 patients were analyzed for their Clinical records, laboratory results including the diagnosis of HBV infection MESHD and liver function. Among 123 confirmed COVID-19 patients, the mean age TRANS was 51 years old and 59.3% were females TRANS (73/123). Fifteen were previously HBV infected MESHD patients, 66.7% of them were males TRANS (10/15), patients with HBV infection MESHD appeared to have a higher incidence of liver cirrhosis MESHD cirrhosis HP and an increased level of total bilirubin. Seven (46.7%) patients with HBV infection MESHD were defined as severe cases, while the severity rate was 24.1% for the patients without HBV infection MESHD (26/108). The mortality of patients with HBV infection MESHD was 13.3% (2/15) compared to 2.8% (3/108) for the patients without HBV infection MESHD. Conclusions SARS-CoV-2 infection MESHD may cause liver function damage MESHD in COVID-19 cases and the patients with HBV infection MESHD are likely to have more severe disease outcome.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.